SOMERSET, N.J., Nov. 12, 2019 /PRNewswire-PRWeb/
-- Catalent, the leading global provider of advanced delivery
technologies, development, and manufacturing solutions for drugs,
biologics, gene therapies, and consumer health products, today
announced that Greg Bleck, Ph.D.,
Global Head of R&D, Catalent Biologics will present at the
upcoming annual PEGS Europe conference, which will be held at the
Lisboa Congress Center, Lisbon,
Portugal, on Nov. 18 – 22,
2019.
On Tuesday, Nov. 19 at
3:50 p.m., Dr. Bleck will speak as
part of the conference's "Cell Line and Systems Engineering" track.
His presentation, entitled "GPEx® Boost Technology: A Novel
Approach for High-Expressing CHO Cell Line Engineering," will
demonstrate how Catalent's new cell line technology can allow
greater productivity, streamlined development and the reduction of
cost of goods. The presentation will include case studies to make
comparisons between the traditional GPEx cell line development
technology, used to create high-yielding mammalian cell lines, and
GPEx Boost technologies.
GPEx Boost cell line development technology was launched in
November 2019 and combines Catalent's
proprietary GPEx technology and a glutamine synthase knock-out
Chinese hamster ovary (CHO) cell line.
In his role at Catalent, Dr. Bleck has overall responsibility
for the development and acquisition of new products and
technologies. He was an original employee of Gala Biotech (acquired
by Catalent), where he used his knowledge of gene expression and
transgenic systems to develop and optimize retroviral vector
expression systems and the proprietary GPEx process. Prior to
joining Gala, he performed postdoctoral work at the University of Illinois-Urbana working in the areas
of gene regulation and expression. Dr. Bleck holds a bachelor's
degree and a doctorate in endocrinology-reproductive physiology,
both from the University of
Wisconsin-Madison. He has published over 60 research papers,
co-authored three book chapters, and is the sole inventor or
co-inventor on multiple patents.
For further information on this event, visit
https://www.catalent.com/index.php/news-events/events/PEGS-Europe.
To arrange a meeting with Dr. Bleck or any of the other Catalent
experts attending the event, contact Richard Kerns at NEPR - richard@nepr.agency
About Catalent Biologics
For more than two decades, Catalent Biologics has built
capabilities and experience in development, manufacturing, and
analytical services for new biological entities, gene therapies,
biosimilars, and antibody-drug conjugates. Catalent Biologics has
worked with 600+ mAbs and 80+ proteins, and 12 biopharmaceutical
drugs produced using GPEx® technology have been approved and
marketed, with more than 120+ ongoing clinical trials utilizing
therapeutic candidates developed using the GPEx platform. A further
25 commercially-approved products have employed Catalent Biologics'
capabilities through to aseptic fill/finish. Catalent's latest
addition, Paragon Gene Therapy's AAV development through
commercial-scale manufacturing facilities in Baltimore, Maryland, has produced over 100
clinical GMP batches across 40 programs. Using advanced protein
improvement technology and tailored solutions from DNA through to
clinical and commercial supply, Catalent Biologics brings better
biologic treatments to patients, faster. For more information,
visit biologics.catalent.com
About Catalent
Catalent is the leading global provider of advanced delivery
technologies, development, and manufacturing solutions for drugs,
biologics, gene therapies, and consumer health products. With over
85 years serving the industry, Catalent has proven expertise in
bringing more customer products to market faster, enhancing product
performance and ensuring reliable global clinical and commercial
product supply. Catalent employs nearly 13,000 people, including
approximately 2,400 scientists and technicians, at more than 35
facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is
headquartered in Somerset, New
Jersey. For more information, visit
http://www.catalent.com
More products. Better treatments. Reliably supplied.™
SOURCE Catalent